This guide covers that last category. If you want tirzepatide as a medicine, the path is a prescriber and a pharmacy, full stop. For everyone researching the gray market anyway, here is what the published record shows. PeptideCensus currently tracks 272 vendors selling tirzepatide with 2,813 published third-party tests behind them, the deepest testing record of any compound in our index. That depth is useful: with this much data, a vendor with a thin or stale record has no excuse.
Tirzepatide spent roughly two years on the FDA’s drug shortage list, and during a shortage, compounding pharmacies may legally produce copies of a drug. That window closed. The FDA declared the shortage resolved in December 2024, a federal court declined to block the decision in early March 2025, and enforcement discretion for compounders ended that same month, with 503B outsourcing facilities given until March 19, 2025. The compounded supply that many telehealth clinics were built on went away.
Some of those patients moved to the branded product. A visible share moved to research-chemical vendors instead, and the testing volume in the public record reflects it: tirzepatide is now the most-tested peptide in our dataset by a wide margin, with published results as recent as August 2026.
Zepbound (approved for weight management in November 2023) and Mounjaro (type 2 diabetes, 2022) are the real thing, with SURMOUNT-1 showing up to 20.9% mean weight reduction at 72 weeks on the top dose; the full schedule and per-dose numbers live in our tirzepatide dosage guide. Lilly also sells single-dose Zepbound vials through its own direct-to-patient channel at self-pay prices in the hundreds of dollars per month. Any site offering “compounded tirzepatide” today is worth questioning hard, because the legal basis that once existed is gone, and the FDA has been sending warning letters accordingly. None of this article is medical advice; it documents what the market and the testing record look like.
The tirzepatide leaderboard ranks vendors by our confidence-adjusted score, built from published purity and quantity results against label claims. As of this writing, the top of the table sits in the 89 to 92 range, with individual records running from a dozen to more than fifty published tests per vendor and recent test dates clustered in July and August 2026. Published pricing among those leaders runs about $0.34 to $0.70 per milligram. Every row links to its source, and the table refreshes daily.
Worth saying plainly: a high score here means a vendor’s published batches matched their labels. It does not mean the product is safe for human use, and it never will, because that is not what HPLC testing measures.
Among the highest-scored vendors, published tirzepatide pricing runs $0.34 to $0.70 per milligram as of September 2026. Do the comparison in price per milligram, not per vial. A 10mg vial of verified material runs a few dollars in material terms, which is why the cheap outliers deserve the most suspicion: at some point the economics only work if the vial does not contain what it says. The same math, adjusted for tested content, sits alongside every score on the vendor rankings.
No. The shortage that permitted it was declared resolved in December 2024, and compounders’ grace periods ended in March 2025. Offers of compounded tirzepatide today operate outside that framework.
It occupies the same gray zone as other research chemicals: sold for laboratory use only, not for human consumption, with regulators targeting sellers who market it as a medicine.
Open the tirzepatide page, find the vendor in the leaderboard, and click through to the published tests. Then confirm the COA for your specific batch verifies on the issuing lab’s site.
You are paying for raw material without manufacturing controls or any accountability behind it, versus a finished pharmaceutical. The price gap is the risk, priced in.
We do not hand-pick winners. The ranking is generated from the published record and changes as new results publish, so the honest answer is whatever the live table says today.
Whoever you buy from, look up their record first, verify the batch COA against the lab’s database, and only then run your numbers through the peptide calculator. Buying from Canada? The Canada guide covers the differences. And if you are researching the next compound in this class, our retatrutide guide covers a market with none of tirzepatide’s legal routes.
PeptideCensus Editorial is the research team behind the independent peptide lab-result index. Every article is built from published third-party data - trial publications, lab reports, and regulatory records - with every number linked to its source. We don't test, we don't sell, and commissions never touch scores or rankings.
About PeptideCensus →